Health and Healthcare

How Insys Is Winning With This FDA Update

courtesy of the U.S. Food and Drug Administration

Insys Therapeutics Inc. (NASDAQ: INSY) shares made a handy gain early on Thursday after the company announced an update from the U.S. Food and Drug Administration (FDA).

Specifically, the FDA granted a Fast Track designation to the company’s epinephrine nasal spray as an investigational treatment for anaphylaxis, an acute, life-threatening allergic reaction requiring urgent treatment.

In a previous clinical trial, the intranasal epinephrine product showed promise as a potential needle-free, non-invasive and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis. Preliminary results demonstrated rapid drug absorption with the epinephrine nasal spray and showed that the intranasal delivery was similar to that of intramuscular injection with EpiPen.

According to the Mayo Clinic, more than 200,000 cases of anaphylaxis occur each year in the United States. The World Allergy Organization estimates that up to 2% of the global population — as many as 150 million people worldwide — will experience anaphylaxis during their lifetime.

Steve Sherman, senior vice president of regulatory affairs for Insys Therapeutics, commented:

The receipt of Fast Track designation represents a significant milestone for INSYS and our clinical development of this novel drug-device combination. We look forward to working with the agency to make it available to those who may be interested in an alternative to intramuscular auto-injectors as soon as possible.

Shares of Insys traded after Thursday’s opening bell at $8.75, or up about 10%. The consensus analyst price target is $9.60, and the 52-week trading range is $4.10 to $14.00.

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

  1. Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
  2. Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
  3. Choose Your  Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!

 

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.